Overview

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Status:
Not yet recruiting
Trial end date:
2024-08-02
Target enrollment:
Participant gender:
Summary
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline